Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics

被引：43

作者：

Dahl, ML ^{[1
]}

Sjöqvist, F ^{[1
]}

机构：

[1] Karolinska Inst, Huddinge Univ Hosp, Dept Med Lab Sci & Technol, Div Clin Pharmacol, SE-14186 Huddinge, Sweden

来源：

THERAPEUTIC DRUG MONITORING | 2000年 / 22卷 / 01期

关键词：

pharmacogenetics; antidepressants; neuroleptics;

D O I：

10.1097/00007691-200002000-00024

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

A short review of the metabolism of psychoactive drugs and the pharmacogenetic factors regulating the enzymes involved is presented hen. The potential clinical usefulness of phenotyping and genotyping individuals, with regard to their drug metabolic capacity, is discussed. Indications for genotyping CYP2D6 and a flow scheme for the combined use of conventional therapeutic drug monitoring (TDM) and pharmacogenetic methods for optimizing dosage-schedules of psychoactive drugs are suggested.

引用

收藏

页码：114 / 117

页数：4

相关论文

共 25 条

[1] PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].

AGUNDEZ, JAG ;

LEDESMA, MC ;

LADERO, JM ;

BENITEZ, J .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269

[2] STEADY-STATE PLASMA LEVELS OF NORTRIPTYLINE INTWINS - INFLUENCE OF GENETIC FACTORS AND DRUG THERAPY [J].

ALEXANDERSON, B ;

EVANS, DAP ;

SJOQVIST, F .

BMJ-BRITISH MEDICAL JOURNAL, 1969, 4 (5686) :764-+

[3] PREDICTION OF STEADY-STATE PLASMA LEVELS OF NORTRIPTYLINE FROM SINGLE ORAL DOSE KINETICS - STUDY IN TWINS [J].

ALEXANDERSON, B .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1973, 6 (01) :44-53

[4] GENETIC CONROL OF NORTIPTYLINE KINETICS IN MAN - STUDY OF RELATIVES OF PROPOSITI WITH HIGH PLASMA CONCENTRATIONS [J].

ASBERG, M ;

EVANS, DAP ;

SJOQVIST, F .

JOURNAL OF MEDICAL GENETICS, 1971, 8 (02) :129-&

[5] EXTREMELY RAPID HYDROXYLATION OF DEBRISOQUINE - A CASE-REPORT WITH IMPLICATION FOR TREATMENT WITH NORTRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANTS [J].

BERTILSSON, L ;

ABERGWISTEDT, A ;

GUSTAFSSON, LL ;

NORDIN, C .

THERAPEUTIC DRUG MONITORING, 1985, 7 (04) :478-480

[6] MOLECULAR-BASIS FOR RATIONAL MEGAPRESCRIBING IN ULTRARAPID HYDROXYLATORS OF DEBRISOQUINE [J].

BERTILSSON, L ;

DAHL, ML ;

SJOQVIST, F ;

ABERGWISTEDT, A ;

HUMBLE, M ;

JOHANSSON, I ;

LUNDQVIST, E ;

INGELMANSUNDBERG, M .

LANCET, 1993, 341 (8836) :63-63

[7] Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders [J].

Bertilsson, L ;

Dahl, ML .

CNS DRUGS, 1996, 5 (03) :200-223

[8] DEBRISOQUINE SPARTEINE HYDROXYLATION GENOTYPE AND PHENOTYPE - ANALYSIS OF COMMON MUTATIONS AND ALLELES OF CYP2D6 IN A EUROPEAN POPULATION [J].

BROLY, F ;

GAEDIGK, A ;

HEIM, M ;

EICHELBAUM, M ;

MORIKE, K ;

MEYER, UA .

DNA AND CELL BIOLOGY, 1991, 10 (08) :545-558

[9] CYP2D6 GENOTYPE DETERMINATION IN THE DANISH POPULATION [J].

BROSEN, K ;

NIELSEN, PN ;

BRUSGAARD, K ;

GRAM, LF ;

SKJODT, K .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 47 (03) :221-225

[10] GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS [J].

DAHL, ML ;

YUE, QY ;

ROH, HK ;

JOHANSSON, I ;

SAWE, J ;

SJOQVIST, F ;

BERTILSSON, L .

PHARMACOGENETICS, 1995, 5 (03) :159-164